Current treatment of sepsis and endotoxaemia

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 6, 2000, Pages 1203-1217

  Periti, Piero ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antimicrobial chemotherapy; Endotoxaemia; Phannacodynamics; Phannacokinetics; Sepsis; Septic shock

Indexed keywords

ANTIINFECTIVE AGENT;

ANIMAL; CLINICAL TRIAL; ENDOTOXEMIA; HUMAN; MICROBIOLOGY; REVIEW; SEPSIS; SEPTIC SHOCK;

ANIMALS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; ENDOTOXEMIA; HUMANS; SEPSIS; SHOCK, SEPTIC;

EID: 0034280817     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.6.1203     Document Type: Article

References (59)

1. VINCENT J-L: New therapies in sepsis. Chest (1997) 112-.330S-338S. •None of the compounds investigated within new therapies for sepsis liave consistently improved the outcome because the research approach has been too narrowly focused. Attempts to completely block the sepsis response deprive the host of an essential defence mechanism.
2. NYSTRÖM P-O: The systemic inflammatory response syndrome: definitions and aetiology. J. Antimicrob. Chemother. (1998) 4l(Suppl. A):l-7.
3. GULLO A: Sepsis and organ dysfunction/failure. An overview. Minerva Anestiol. (1999) 65(7-8)029-540.
4. BONE RC, BALK RA, CERRA FB etal.: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest (1992) 101:1644-1655.
5. GLAUSER MP, HEUMANN D, BAUMGARTNER JD, COHEN J: Pathogcncsis and potential strategics for prevention and treatment of septic shock: an update. Clin. Infect. Dis. (1994) 18(Suppl. 2):S205-S2l6.
6. NATANSON C, DANNER RL, ELIN RJ et al.: Role of cndotoxemia in cardiovascular dysfunction and mortality. Escbertcbla coll and Stapbylococcus aurais challenges in a canine model of human septic shock./ Clin. Infest. (1989) 83:243-251.
7. CHABY R: Strategies for the control of LPS-mediated pathophysiological disorders. Drug Discov. Today (1999)4(5):209-221.
8. FINCH RG: Design of clinical trials in sepsis: problems and pitfalls. / Antimicrob. Cbemotber. (1998) 4l(Suppl. A):95-102.
9. MICHIE HR: The value of animal models in the development of new drugs for the treatment of the sepsis syndrome. / Antimicrob. Cbemotber. (1998) 4l(Suppl. A):47-49.
10. QUEZADO MIN, NATANSON C, AILING DW et al.: A controlled trial of HA-1A in a canine model of Gram-negative septic shock. / Am. Med. Assoc. (1993) 269:2221-2227.
11. PERITI P, MAZZEI T: Antibiotic-induced release of bacterial cell wall components in the pathogènes is of sepsis and. septic shock: a review. J. Chemother. (1998) 10(6):427-448.
12. DINARELLO CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogcnesis of septic shock. Chest (1997) 112(6):321S-329S. Biological properties of IL-1 and TNF mimic host responses to infection, inflammation, injury or immunologie challenge. In animal models of systemic inflammation, such as septic shock, specific blockade of either IL-1 or TNF results in a reduction in the severity of the inflammatory response.
13. PERITI P, MAZZEI T: New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock - Review article. Int. J. Antimicrob. Chemother. (1999) 12:97-105-The risk of septic shock in a septic patient depends on whether the patient is immunocompromised and on the dimension of the bacterial load, which can affect the efficacy (inoculum effect) of antimicrobial therapy administered. In the course of severe sepsis, it is very important to use antimicrobial agents which induce rapidly and prevalently fragile aberrant cells or spheroplasts, and thus are rapidly bactericidal.
14. PERITI P, MAZZEI T: Opinion - antimicrobial therapy for sepsis and septic shock: time for a change. Autibiot. Chemother. (1999) 3(2):15-l6.
15. NORIMATSU M, MORRISON DC: Correlation of antibiotic-induced cndotoxin release and cytokine production in Escbericbia coli - inoculated mouse whole bloode.v vlvo.J. Infect. Dis. (1998) 177:1302-1307.
16. ENG RHK, CHERUBIN C, SMITH SM, BUCC1NIF: Inoculum effect of β-lactam antibiotics on Enterobacteriaceae. Antimicmb. Agents Cbemotber. (1985) 28(2):601-606.
17. DAVEY PG, BARZA M: The inoculum effect with Gram-negative bacteria I'M vitro and in vivo.J. Antimicmb. Chemother. (1987) 20:639-644.
18. REILLY J, COMPAGNON A, TUORNIER P, BASTIN R, DUBUIT H: Les accidents du traitment des fièvres typhoïdes par la chloromycetine. Ann. Med. (Paris) (1950) 51:597-629.
19. SHENEP JL, FLYNN PM, BARRETT FF, STIDHAM GL, WESTENKIRCHNER DF: Serial quantitation of cndotoxcmia and bactcrcmia during therapy for Gram-negative bacterial sepsis - Concise communications./ Infect. Dis. (1988) 157(3):565-568.
20. FRIELING JTM, MULDER JA, HENDRIKS T, CURFS JHAJ, VAN DER LINDEN CJ, SAUERWEIN RW: Differential induction of pro-and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Antimicrob. Agfnts Chemother. (1997) 4l(7):l439-1443.
21. SHENEP JL, BARTON RP, MOGAN KA: Role or antibiotic class in the rate of liberation of cndotoxin during therapy for experimental Gram-negative bacterial sepsis. / Infect. Dis. (1985) 151:1012-1018.
22. GEMMEL C, LORIAN V: Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence and susceptibility to immunodefenscs: clinical significance. In: Antibiotics in Laboratory Medicine (4th Edition). Lorian V (Ed.), Williams and Wilkins, Baltimore, USA (1996):397-452.
23. KIRIKAE T, NAKANO M, MORRISON DC: Antibioticinduced cndotoxin release from bacteria and its cUnical significance - Review. Microbiol. Immnnol. (1997) 4l(4):285-294.
24. ENG RHK, HSIEH A, SMITH SM: Antibiotic killing of bacteria: comparison of bacteria on surfaces and in liquid, growing and non-growing. Chemotherapy(1995) 41:113-120.
25. PUCCIMJ, BOICE-SOWEKJ, KESSLER RE, DOUGHERTY TJ: Comparison of cefcpime, cefpirome and cefaclidine binding affinities for penicillin-binding proteins in Escbericbia coli K-12 and Pseudomonas aerugiiiosa SC8329. Antimicrob. Agents Chemother. (1991) 35(1D:2312-2317.
26. LORIAN V: Phagocytosis of staphylococci after exposure to antibiotics./ Anlimicrob. Chemolber. (1985) 16:129-133-
27. SATTA G, CORNAGLIA G, MAZZARIOL A, GOLINI G, VALISENA S, FONTANA R: Target for bacteriostatic and bactericidal activities of β-lactam antibiotics against Escbericbla coll resides in different penicillinbinding proteins. Antimicrob. Agents Chcmother (1995) 39):812-818. β-lactam antibiotics cause bactericidal effects of very different intensities, depending on the PBPs that are partially or fully saturated. The intensity of the bactericidal effect is lowest when the antibiotics bound and saturated only one of the essential PBPs, higher when two of them were bound and highest when all three essential PBPs were saturated.
28. HOLZHEIMER RG: The significance of endotoxin release in experimental and clinical sepsis in surgical patients - Evidence for antibiotic-induced endotoxin release? Infection (1998) 26(2):77-84.
29. STRATTON CW: Mechanisms of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics. In: Antibiotics in Laboratory Medicine (4th Edition). Lorian V (Ed.), Williams and Wilkins, Baltimore, USA (1996)079-603.
30. GOULD IM: Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents./ Chemother. (1997) 9(SuppI. l):7-i-83. Optimal cidal activity of β-lactam antibiotics may be achieved only when all crucial heavy weight PBPs are saturated, which may be at concentrations approaching 100, or even 1000, times the MIC, depending on factors such as the inoculum and specific binding site preferences. At these concentrations, spheroplasts form and rapid bacterial cell lysis occurs. Depending on the antibiotic, these high concentration levels can be achieved in vivo for manyorganisms but only at higher doses than are normally administered.
31. LI RC, ZHU ZY:/ii vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective. / Chemother. (1997) 9(Suppl. 1)05-63.
32. CRAIG WA: Interrelationship between pharmacokinctics and pharmacodynamics in determining dosage regiments for broad-spectrum ccphalosporins. Diagn. Microbiol. Infect. Dis. (1995) 22:89-96.
33. SCHENTAG J: Pharmacokinetic issues and implications. 2nd Etimpean Congress of Chemotherapy and lib Biennal Conference on Anti-infective Agents and Chemotherapy, May 10-13, 1998 Hamburg, Final Pmgramme. Futuramed, Germany (1998):9-i.
34. KITSCHE D, SCHULZE C, CESSER S, DALHOFF A, SACK M: Impact of different classes of antimicrobial agents on plasma endotoxin activity. Arch. Stirg. (1996) 131:192-199.
35. CRAIG WA: Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. (1996) 25:213-217.
36. VOGELMAN B, GUDMUNDSSON S, LEGGETT J, TURNIDGE J, EBERT S, CRAIG WA: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect. Dis. (1988) 158:831-847.
37. HYATT JM, MCKINNON PS, ZIMMER GS, SCHENTAG JJ: Tlie importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin. Pharmacokinet. (1995) 28:143-160.
38. FORREST A, NIX DE, BALLOW CH, GOSS TF, BIRMINGHAM MC, SCHENTAG JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Cbemotber. (1993) 37:1073-1081.
39. GOSS TF, FORREST A, NIX DE et al.: Mathematical examination of dual individual principles. II. The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoximc. Ann. Pharmacother. (1994) 28:863-868.
40. THOMAS JK, FORREST A, BHAVNANI SM eta!.: Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Anlimicrob. Agents Chemother. (1998) 42(3)021-527. The probability of developing bacterial resistance during therapy increases significantly when the antimicrobial exposure corresponds to an AUCo - 24/M'C ratio of < 100. Dosing regimens which provide a ratio of at least 100 appear to reduce the rate of the development of bacterial resistance intratherapy in acutely ill patients.
41. TRAUTMANN M, ZICK R, RUKAVINA T, CROSS AS, MARRE R: Antibiotic-induced release of endotoxin: in vitro comparison of meropenem and other antibiotics. / Antimicrob. Cbemotber. (1998) 41:163-169.
42. YOURASSOWSKY E, VAN DER LINDEN MP, LISMONT MJ, CROKAERT F: Turbidflnetric and microscopic analysis of Baclcroides fragilis exposed to tazobactam and piperacillin alone and in combination. Chemotherapy (1990) 36:215-221.
43. QADRI SM, UENO Y, CUNHA BA: Susceptibility of clinical isolates to expanded-spectrum bcta-lactarns alone and in the presence of bcta-lactamasc inhibitors. Chemotherapy (1996) 42(5):334-342.
44. BOHME A, SHAH PM, STILLE W, HOELZER D: Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Enr.J. Meet. Res. (1998) 3(7):324-330.
45. FONTANA R, VALISENA S, CORNAGLIA G: Comparative affinities for penicillin-binding proteins of multipolar ionic amphoteric ccphalosporins in Gram-negative bacteria./ Cbemotber. (1996) 8(Suppl. 2):23-30.
46. PERITI P, NICOLETTI P: Classification of beta-lactam antibiotics according to their pharmacodynamics. J. Chemother. (1999) 11(5):323-330. Different affinities of β-lactam antibiotics for PBPs mayexplain the differences in grown bacterial patterns, suggesting three main responses to this kind of antimicrobial agents. Three classes of agents are delineated by the extent of PBP pattern saturation, bacterial biomass increase, PAE length and initial killing power. Some antibiotics do not liave the propensity to provoke septic shock because their mechanism of action is rapidly bactericidal, such as the carbapenems, the cephems ceftriaxone and cefepime, the glycopeptides, some aminoglycosides and fluoroquinolones.
47. ARTENSTEIN AW, CROSS AS: Inhibition of endotoxin reactivity by aminoglycosides.J. A ntimicrob. Cbemotber. (1989) 24(5):826-828.
48. FOCA A, MATERA G, IANNELLO D, BERLINGHIERI MC, LIBERTO MC: Aminoglycosides modify the in vitro mctachromatic reaction and murine generalized Schwartzman phenomenon induced by Salmonella Minnesota R595 Iipopolysaccharide./li/jnj/crub..4ge;iJ.J Cbemotber. (1991) 35:2161-2164.
49. FOCA A, MATER G, DERLINGHIERI MC, LIBERTO MC, DE SARRO GB: Teicoplanin reduces in vitro reactivity and murine lethality of Salmonella Minnesota R595 lipopolysaccharide. / Aiitimicrob. Chemother. (1992) 29:443-446.
50. FOCA A, MATERA G, BERLINGHIERI MC: Inhibition of endotoxin-induced interlcukin 8 release by tcicoplanin in human whole blood. Enr. J. Clin. Micmbiol. Infect. Dis. (1993) 12:940-944.
51. SIEDLAR M, SZCZEPANIK A, WIECKIEWICZ J, PITUCHNOWOROLSKA A, ZEMBALA M: Vancomycin down-regulates lipopolysaccharidc-induccd tumour necrosis factor alpha (TNF-ct) production and TNF-a-mRNA accumulation in human blood monocytes - Short communication. Immunopbarmaro/ogy (1997) 35:265-271.
52. HACK CE, HART M, STRACK VAN SCHIJNDEL RJM et al.: Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect. Immun. (1992) 60:2835-2842.
53. KIRIKAE T, KIRIKAE F, SAITO S et al.: Biological characterization of cndotoxins released from antibiotictreated Pseudomonas aeruginosa and Escbericbta coli. Aiitimicrob. Agents Chemother. (1998) 42(5):1015-1021.
54. MOCK CN, JURKOVICH GJ, DRIES DJ, MAIER RV: Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch. 5/g.(1995) 130:1234-1241.
55. PRINS JM, VAN AGTMAEL MA, KUIJPER EJ, VAN DEVENTER SJF, SPEELMAN P: Antibiotic-induced endotoxin release in patients with Gram-negative uroscpsis: a double-blind study comparing imipcnem and ceftazidime.J. Infect. Dis. (1995) 172:886-891.
56. PERIT1 P, MAZZEI T, DE GAUDIO AR, TONELLI F: Attuali orientamenti nclla scella c modalità di somministrazionc degli agent! antimicrobici per una rationale chcmiotcrapia dclla scpsi grave. Farm. Ter. (1998) X\'(l/2):3-23.
57. STUERTZ K, SCHMIDT H, EIFFERT H, SCHWARTZ P, MÄDER M, NAU R: Differential release of lipoteichoic and tcichoic acids from Streptococcus piieumontac as a result of exposure to β-Iactam antibiotics, rifamycins, trovafloxacin, quinupristin-dalfopristin. Antimicrob. Agents Cbemotber. (1998) 42(2):277-281.
58. VAN DER BERG C, DE NEELING AJ, SCHOT CS, HUSTINX WNM, WEMER J, DE WILDT DJ: Delayed antibioticinduced lysis ofEscberlcbia colt in vitro is correlated with enhancement of LPS release. Scand.J. Infect. Dis. (1992) 24:619-627.
59. HORII T, KOBAYASHI M, SATO K, ICHIYANA S, OHTA M: An in vitro study of carbapenem-induccd morphological changes and endotoxin release in clinical isolates of Gram-negative bacilli. J. Antimicrob. Cbemother. (1998) 41:435-442.